Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.50 | -2.70 | -14.92 | -1.21 |
| FCF Yield | 4.19% | -0.55% | 4.68% | 8.96% |
| EV / EBITDA | 12.91 | 14.62 | 12.54 | 11.68 |
| Quality | ||||
| ROIC | 7.40% | 5.19% | 6.95% | 7.26% |
| Gross Margin | 77.77% | 77.42% | 74.58% | 77.56% |
| Cash Conversion Ratio | 1.68 | 1.51 | 1.40 | 1.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 11.47% | 12.52% | 7.18% | 2.91% |
| Free Cash Flow Growth | 1,026.64% | -114.84% | -37.49% | 274.45% |
| Safety | ||||
| Net Debt / EBITDA | 1.68 | 2.71 | 1.28 | 1.72 |
| Interest Coverage | 4.54 | 3.66 | 8.33 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 1.39 | 1.29 | 1.43 | 1.02 |
| Cash Conversion Cycle | 313.10 | 321.31 | 278.25 | 401.51 |